The Indian pharmaceutical industry is the largest supplier of cost effective generic medicines to the developed world. With the widest range of medicines available for exports and with the availability of the largest number of approved pharmaceutical manufacturing facilities, India is all set to become the leader of pharmaceutical exports to the world. According to …
Continue reading “Indian pharmaceutical exports: The growth story”
The blood pumping mechanism of the body, ie the heart, is one of the most important organs in the human body. This is one of the organs which experiences extensive stress. The stress which the human heart goes through is because of both internal and external factors. Some of the factors could be genetic in …
Continue reading “The cardio factor: An insight into heart disease”
Patent expiration: The generic factor Key companies like Amgen, Pfizer, Roche, BMS and Novartis have their bestselling patented brands used for curing life threatening diseases facing patent expirations. The question then arises as to what these companies must do in order to ‘save’ their brands which have acceptability among the payers in the US and …
Continue reading “Future of branded drugs in a generic world”
Where there is sugar, there are ants and ants are considered to be the most diligent living forms. But when it comes to the sugar disease, ie, diabetes, it is highly challenging to achieve the desired results in clinical trials but also the right investigators and funding for those trials too. Needless to say, the …
Continue reading “Diabetes cure: An insight into research post exit of glitazones”
The popular saying ‘United we stand, divided we fall’ is a popular phrase which signifies various aspects of coming together for a common goal or a purpose. This has been a recurring feature for the global pharmaceutical industry as well. As pressures on drug manufacturing, research and development and regulatory aspects have been on the …
Continue reading “Whats driving mergers and acquisitions in pharma industry?”
Funding is difficult to come by for pain killer research since challenges of data collection for clinical trials is high as compared to any other therapeutic area. The dimension of physical pain for human beings range from a minor back pain to low back pain, back pain, osteoarthritis/rheumatoid arthritis, joint pain, muscle pain, neuropathic pain, …
Continue reading “Is global pharma industry investing enough in pain killer research?”
CNS disorders rake in more than $ 80 billion a year for the pharma industry, however higher failure rates in clinical trials are forcing big companies to cut down their spend on CNS drug R&D. The most complicated area of clinical research post 2013 is the central nervous system (CNS). Big pharmaceutical companies are keen …
Continue reading “CNS drug research: A dilemma for big pharma companies”